P359: IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

P359: IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Bibliographic Details
Main Authors:	F. Locatelli, G. Zugmaier, C. Rizzari, J. Morris, B. Gruhn, T. Klingebiel, R. Parasole, C. Linderkamp, C. Flotho, A. Petit, C. Micalizzi, Y. Zeng, R. Desai, W. Kormany, C. Eckert, A. Möricke, M. Sartor, O. Hrusak, C. Peters, V. Saha, L. Vinti, A. von Stackelberg
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000844324.04051.5b

Similar Items

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
by: Hagop M. Kantarjian, et al.
Published: (2023-10-01)

Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen
by: Christina Peters, et al.
Published: (2024-09-01)

Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases
by: Yi-Lun Wang, et al.
Published: (2024-06-01)

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
by: Nicola Gökbuget, et al.
Published: (2019-10-01)

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL
by: Guenter Henze, et al.
Published: (2024-06-01)

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
by: Brice Mouttet, et al.
Published: (2019-06-01)

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2024-08-01)

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia
by: Anthony S. Stein, et al.
Published: (2018-07-01)

Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series
by: Guichi Zhou, et al.
Published: (2023-02-01)

BLINATUMOMAB BRIDGING THERAPY FOR EFFECTIVE MANAGEMENT OF MRD IN PRO-B ALL WITH CNS INVOLVEMENT: A CASE REPORT OF POST TRANSPLANT PATIENT AT 23 MONTHS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION
by: Ceren Dehri Bahşi, et al.
Published: (2024-12-01)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
by: Mark Litzow, et al.
Published: (2023-08-01)

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
by: Nicolas Boissel, et al.
Published: (2023-01-01)

Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
by: Richard Burt, et al.
Published: (2019-03-01)

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
by: Patrick Schlegel, et al.
Published: (2014-07-01)

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
by: Vera Dufner, et al.
Published: (2019-08-01)

Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation
by: Mattia Algeri, et al.
Published: (2024-10-01)

Blinatumomab added to conditioning regimen of allogeneic hematopoietic stem cell transplantation for adult MRD-positive acute lymphoblastic leukemia: a single-center case series
by: Hui Fu, et al.
Published: (2025-12-01)

Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
by: Elias J. Jabbour, et al.
Published: (2024-11-01)

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
by: Nicola Gökbuget, et al.
Published: (2017-04-01)

Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
by: Yurou Chu, et al.
Published: (2025-02-01)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
by: Jiao Xie, et al.
Published: (2023-08-01)

All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia
by: Reza Mirfakhraie, et al.
Published: (2024-04-01)

Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia
by: Yamini K. Kathari, et al.
Published: (2024-03-01)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020-06-01)

Pomara, B. (2022), Refugiados, Los moriscos e Italia. Granada: Comares, 359 pp.
by: Bernard Vincent
Published: (2023-07-01)

Association of HLA-C*07:359 with HLA-A, -B, and -DRB1 alleles in Taiwanese
by: Kuo-Liang Yang, et al.
Published: (2024-01-01)

P1263: A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES
by: L. Hebert, et al.
Published: (2022-06-01)

P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE
by: Sabina Chiaretti, et al.
Published: (2023-08-01)

Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation
by: Aida Zeckanovic, et al.
Published: (2025-02-01)

PB1738: OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B – ALL WITH INVALID OR RECURRENT CART
by: Lin Yuehui
Published: (2023-08-01)

Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022-10-01)

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia
by: Vossough P, et al.
Published: (2005-07-01)

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia
by: P Vossough, et al.
Published: (2005-06-01)

P1402: INFUSION OF 14 DAYS BLINATUNOMAB IN COMBINATION WITH CHEMOTHERAPY FOR 46-DAY MRD+ PEDIATRIC B-ALL PATIENTS IN INTERMEDIATE/HIGH-RISK GROUP RESULTS IN MRD CONVERSION.
by: Changwen Xue, et al.
Published: (2023-08-01)

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
by: Vinodh Pillai, et al.
Published: (2019-11-01)

Reduced‐dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B‐cell acute lymphoblastic leukemia
by: Jing Lu, et al.
Published: (2024-03-01)

Corrigendum: Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022-12-01)

Expression pattern of CD179 in b-cell acute lymphoblastic leukemia (B-All): A potential utility for lineage assignment and B-ALL MRD monitoring
by: Tembhare Prashant, et al.
Published: (2022-01-01)

The Moscow puzzles : 359 mathematical recreations /
by: 403620 Kordemsky, Boris A.
Published: (1972)

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
by: N. Short, et al.
Published: (2022-06-01)